MERCK & CO., INC. (MRK)
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
📈 **POSITIVE** • Medium confidence analysis (77%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business